Bulevirtide receives conditional marketing authorization in the EU

Bulevirtide, an antiviral that blocks the entry of hepatitis B and D viruses into hepatocytes, has been approved as the first treatment option for adult patients with chronic hepatitis delta virus infection and compensated liver disease in Europe.

Source:

Biospace Inc.